Methods and compositions for inducing protective immunity against RSV infection
Compositions, vaccines and methods using adenovirus vectors for inducing protective immunity against a respiratory syncytial virus (RSV) infection are described.
1. A vaccine combination comprising:
(i) a first composition comprising an immunologically effective amount of a first adenovirus vector comprising a nucleic acid encoding an antigenic respiratory syncytial virus (RSV) protein having the amino acid sequence of SEQ ID NO: 1 or 2; and
(ii) a second composition comprising an immunologically effective amount of a second adenovirus vector comprising a nucleic acid encoding an antigenic RSV protein having the amino acid sequence of SEQ ID NO: 1 or 2,
wherein one of the compositions is a priming composition and the other composition is a boosting composition.
2. The vaccine combination according to claim 1 , further comprising:
(iii) a third composition comprising an immunologically effective amount of a third adenovirus vector comprising a nucleic acid encoding an antigenic RSV protein.
3. The vaccine combination according to claim 2 , wherein the third adenovirus vector comprises a nucleic acid encoding an RSV F protein having the amino acid sequence of SEQ ID NO: 1 or 2.
4. The vaccine combination according to claim 1 , wherein the adenovirus vectors are recombinant Ad26 vectors.
5. A method of inducing an immune response against RSV in a subject, the method comprising:
(i) administering to the subject a first composition comprising an immunologically effective amount of a first adenovirus vector comprising a nucleic acid encoding an antigenic RSV protein; and
(ii) administering to the subject a second composition comprising an immunologically effective amount of a second adenovirus vector comprising a nucleic acid encoding an antigenic RSV protein,
wherein the adenovirus vector in the first composition (i) comprises a nucleic acid encoding an RSV protein having the amino acid sequence of SEQ ID NO: 1 or 2, and the adenovirus vector in the second composition (ii) comprises a nucleic acid encoding an RSV protein having the amino acid sequence of SEQ ID NO: 1 or 2.
6. The method according to claim 5 , further comprising:
(iii) administering to the subject a third composition comprising an immunologically effective amount of an adenovirus vector comprising a nucleic acid encoding an antigenic RSV protein.
7. The method according to claim 6 , wherein the adenovirus vector in the third composition comprises a nucleic acid encoding an RSV F protein having the amino acid sequence of SEQ ID NO: 1 or 2.
8. The method according to claim 5 , wherein the adenovirus vectors are Ad26 vectors.
9. The method according to claim 5 , wherein step (i) and step (ii) of the method are conducted 1-12 weeks apart.
10. The method according to claim 6 , wherein step (ii) and step (iii) of the method are conducted 1-12 weeks apart.
11. The method according to claim 5 , wherein the subject is a child of about 0 to 24 months of age.
12. The method according to claim 5 , wherein step (i) is conducted in an infant of about 0-2 months of age.
13. The method according to claim 5 , wherein the first composition is administered to an infant at about 2 months of age and the second composition is administered to said infant at about 3 or 4 months of age.
14. The method according to claim 6 , wherein the first composition is administered to an infant at about 2 months of age and the second composition is administered to said infant at about 3 or 4 months of age and the third composition is administered to said infant at about 4 or 6 months of age.